India Pharma Outlook Team | Thursday, 31 July 2025
The Kingdom of Saudi Arabia (KSA) is contacting Indian pharmaceutical and medical device businesses for strategic partnerships and investment in its quickly growing healthcare sector, which is a significant step towards strengthening bilateral economic ties and healthcare collaboration.
On August 18, 2025, the Public Investment Fund (PIF) of Saudi Arabia and the Indian Embassy in Riyadh will host a special webinar aimed at Indian producers of pharmaceuticals and medical devices. Under its Vision 2030 framework, the effort is a component of Saudi Arabia's larger plan to localize healthcare manufacturing, improve supply chain resilience, and draw in foreign investment. With a focus on the webinar as a means of learning more about the Saudi government's procurement procedures, regulatory frameworks, and localization incentives, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) has formally invited its member companies to participate.
“Indian pharma companies have been urged to explore key business avenues, regulatory guidance, and potential collaborations with major Saudi Arabia stakeholders including the Public Investment Fund (PIF), the Saudi Food and Drug Authority (SFDA), National Unified Procurement Company (NUPCO), the Ministry of Investment and other healthcare regulators and procurement bodies,” said Raja Bhanu, Director General (DG), Pharmexcil.
“This is a valuable opportunity for Indian exporters to understand Saudi Arabia’s evolving healthcare ecosystem and the emerging prospects for joint ventures, technology transfer, and investment. We urge all member companies to actively participate. Indian companies interested in participating can connect with Lakshmi Prasanna, Senior Director at Pharmexcil, for registration and further details,” the Pharmexcil DG further informed.
Also Read: Glenmark and AbbVie USD 2 Bn Deal Signals India's Biotech Breakthrough
The strategic advantages of this partnership include the creation of high-value jobs, the promotion of knowledge transfer, the development of the local industrial base and pharmaceutical ecosystem, and a contribution to national drug security by lowering dependency on imports.
